GlassScriptPhysician profile
Julie Demartini
NPI 1316299449
$2,977.22
in general payments reported to CMS, 2019-2025
15 companies · $481 in 2025
The $481 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $250 · 2021: $278 · 2022: $512 · 2023: $531 · 2024: $245 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $732.14 | 2019-2021 | |
| Glaukos Corporation | $455.95 | 2022-2025 | |
| Horizon Therapeutics Plc | $367.61 | 2023 | Tepezza |
| Genzyme Corporation | $205.57 | 2019-2022 | |
| Coopervision INC. | $150.02 | 2021-2025 | Misight Contact Lens, Myday Contact Lens |
| Visioneering Technologies, INC. | $142.68 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $138.50 | 2023 | Acuvue |
| Lkc Technologies, INC. | $130.15 | 2025 | |
| Abbvie INC. | $124.59 | 2022 | |
| Kala Pharmaceuticals, INC. | $118.39 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $117.88 | 2025 | Xdemvy |
| Amgen INC. | $117.56 | 2024 | Tepezza |
| Alcon Vision LLC | $89.29 | 2019-2024 | Precision 1 |
| Maculogix, INC. | $68.20 | 2019 | |
| Bausch & Lomb Americas INC. | $18.69 | 2024 | Infuse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Demartini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.